Getty Images logo

China's Sinovac Ramps Up Production Of Potential COVID-19 Vaccine

BEIJING, CHINA - SEPTEMBER 24: Technicians work in a lab at Sinovac Biotech where the company is producing their potential COVID-19 vaccine CoronaVac during a media tour on September 24, 2020 in Beijing, China. Sinovacs inactivated vaccine candidate, called CoronaVac, is among a number of companies in the global race to control the coronavirus pandemic. The company is running Phase 3 human trials in four countries and ramping up production to 300 million doses per year at a new manufacturing facility south of Beijing. A lack of domestic coronavirus cases in China has meant that companies developing vaccines have shifted their focus overseas to conduct trials to gather the volume of data necessary to win regulatory approvals. When Chinas government launched an emergency use program in July to vaccinate groups of essential workers, Sinovacs chief executive says the company supplied tens of thousands of doses, even as trials are still underway. About 90% of Sinovacs employees have chosen to receive injections of CoronaVac, which is one of eight Chinese vaccine candidates in human trials. The company is also seeking approval to begin clinical trials with teenagers and children as young as age 3.(Photo by Kevin Frayer/Getty Images)
BEIJING, CHINA - SEPTEMBER 24: Technicians work in a lab at Sinovac Biotech where the company is producing their potential COVID-19 vaccine CoronaVac during a media tour on September 24, 2020 in Beijing, China. Sinovacs inactivated vaccine candidate, called CoronaVac, is among a number of companies in the global race to control the coronavirus pandemic. The company is running Phase 3 human trials in four countries and ramping up production to 300 million doses per year at a new manufacturing facility south of Beijing. A lack of domestic coronavirus cases in China has meant that companies developing vaccines have shifted their focus overseas to conduct trials to gather the volume of data necessary to win regulatory approvals. When Chinas government launched an emergency use program in July to vaccinate groups of essential workers, Sinovacs chief executive says the company supplied tens of thousands of doses, even as trials are still underway. About 90% of Sinovacs employees have chosen to receive injections of CoronaVac, which is one of eight Chinese vaccine candidates in human trials. The company is also seeking approval to begin clinical trials with teenagers and children as young as age 3.(Photo by Kevin Frayer/Getty Images)
China's Sinovac Ramps Up Production Of Potential COVID-19 Vaccine
PURCHASE A LICENSE
How can I use this image?
$499.00
USD

DETAILS

Restrictions:
Contact your local office for all commercial or promotional uses.
Credit:
Kevin Frayer / Stringer
Editorial #:
1228686130
Collection:
Getty Images News
Date created:
September 24, 2020
Upload date:
License type:
Release info:
Not released. More information
Source:
Getty Images AsiaPac
Object name:
22b
Max file size:
8256 x 5504 px (27.52 x 18.35 in) - 300 dpi - 13 MB